Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1

Conditions

Astrocytoma 8Glioblastoma 5Prostatic Neoplasms 4Neuroectodermal Tumors, Primitive 4Lymphoma, Non-Hodgkin 4Recurrence 3Lung Neoplasms 3Oligodendroglioma 2Neurocytoma 2Neoplasms 2Glioma 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Brain Neoplasms 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Somatostatinoma 1Small Intestine Cancer 1Small Cell Lung Carcinoma 1Sarcoma 1Salivary Gland Neoplasms 1Rhabdoid Tumor 1Pituitary Neoplasms 1Paranasal Sinus Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Everolimus 5Octreotide 4Leucovorin 4Temozolomide 3Oxaliplatin 3Fluorouracil 3Capecitabine 3vatalanib 2temsirolimus 2Trastuzumab 2Sirolimus 2Melphalan 2Irinotecan 2Biological Therapy 2Bevacizumab 2tipifarnib 1romidepsin 1regorafenib 1pentetreotide 1pazopanib 1napabucasin 1motesanib diphosphate 1irinotecan sucrosofate 1folfirinox 1cixutumumab 1batifiban 1antineoplaston AS 2-1 1antineoplaston A10 1Vinorelbine 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Islet Cell × antineoplaston AS 2-1 × Clear all
NCT00003514 2013-07-10

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicEndocrine

Pituitary Neoplasms, Somatostatinoma, Carcinoma, Merkel Cell, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡